2. Apoptosis
  3. c-Myc
  4. Anticancer agent 84

Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer.

For research use only. We do not sell to patients.

Anticancer agent 84 Chemical Structure

Anticancer agent 84 Chemical Structure

CAS No. : 2714510-72-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 84 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer[1].

IC50 & Target

IC50: 5.0 μM (HepG2); 3.9 μM (MDA-MB-231); ＞100 μM (HBL-100)[1]
In Vitro

Anticancer agent 84 has cytotoxicity in cancer cells (HepG2, MDA-MB-231) and normal cells (HBL-100) with IC50 values of 5.0 μM, 3.9 μM and ＞100 μM, respectively[1].
Anticancer agent 84 displays good c-MYC G4 binding and stabilization abilities[1].
Anticancer agent 84 blocks c-MYC transcription by targeting the promoter G4, leading to c-MYC-dependent cancer cell death in triple-negative breast cancer cell MDA-MB-23[1].
Anticancer agent 84 (2 μM) significantly disrupts the binding of the three proteins (NM23-H2, BLM and DHX36) to c-MYC G4 with IC50 values of 0.16 μM, 2.3 μM and 7.0 μM, respectively[1].
Anticancer agent 84 (0-5 μM) impacts c-MYC-related events in TNBC, including proliferation, invasion, cell cycle, and apoptosis[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 84 Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 48 h
Result: Decreased the mRNA levels of c-MYC.

Cell Cycle Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 24 h
Result: Could arrest MDA-MB-231 cells at the Sub G0 phase.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 24 h
Result: Induced early apoptosis and necrosis in MDA-MB-231 cells.

RT-PCR[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5 μM
Incubation Time: 24 h
Result: Exhibited relatively weak effects on other genes and suppressed c-MYC transcription by targeting c-MYC G4.

Cell Cytotoxicity Assay[1]

Cell Line: MDA-MB-231 cells
Concentration:
Incubation Time: 48 h
Result: Displayed good cytotoxicity against various cancer cells, including MDA-MB-231, MCF-7, HepG2, and SiHa and displayed less cytotoxicity against normal HBL-100 and NCM460 cells.

Cell Proliferation Assay[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 10 days
Result: Exhibits good antiproliferative activity.

Cell Invasion Assay[1]

Cell Line: MDA-MB-231 cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 24 h
Result: Obviously decreased the invasion with an IC50 value of 1.7 μM.
In Vivo

Anticancer agent 84 (i.p.; 2.5 mg/kg; daily; for 24 days) significantly inhibits tumor growth in the MDAMB-231 mouse xenograft model accompanied by c-MYC downregulation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C-nu/nu mice(female, five-week-aged, 10−12 g)[1]
Dosage: 2.5 mg/kg
Administration: intraperitoneally, daily, for 24 days
Result: Exhibited potent antitumor activity and could act as a c-MYC repressor in vivo.
Molecular Weight

994.18

Formula

C57H67N7O9
CAS No.
SMILES

CCN1C2=CC=C(C=C2C3=C1C=CC=C3)C4=NC(C5=CC=C(C=C5)N6CCN(CC6)C)=C(N4C7=CC=C(C=C7)OCCOCCOC8(O[C@@H]9O[C@H]([C@@H]([C@H]([C@@H]9O8)O)O)CO)C)C%10=CC=C(C=C%10)N%11CCN(CC%11)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 84 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 842714510-72-0Anticancer agent84Anticancer agent-84c-MycMycanticancerc-MYCG-quadruplex (G4)cancerHepG2 cellsMDA-MB-231 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 84
Cat. No.:
HY-151471
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.